Daiichi Sankyo announced that the first patient has been dosed in a first-in-human phase 1/2 clinical trial of DS3790, marking the company’s first DXd antibody drug conjugate (ADC) to enter clinical development in hematology. The investigational therapy is being evaluated in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

DS3790 is a potential first-in-class CD37-directed DXd ADC, targeting a protein that is highly expressed on malignant B-cells and for which no approved cancer therapies currently exist. The global study will assess safety, dosing, and preliminary efficacy of DS3790 as a monotherapy, with later cohorts planned to evaluate combinations with other targeted therapies.

Source: Daiichi Sankyo press release